Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vaccinex, Inc. (VCNX : NSDQ)
 
 • Company Description   
Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.

Number of Employees: 40

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.86 Daily Weekly Monthly
20 Day Moving Average: 954,023 shares
Shares Outstanding: 28.45 (millions)
Market Capitalization: $81.37 (millions)
Beta: 1.74
52 Week High: $9.40
52 Week Low: $1.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 22.22% 20.90%
12 Week -4.03% -10.11%
Year To Date 38.16% 22.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1895 MOUNT HOPE AVENUE
-
ROCHESTER,NY 14620
USA
ph: 585-271-2700
fax: 585-271-2765
mrice@lifesciadvisors.com http://www.vaccinex.com
 
 • General Corporate Information   
Officers
Maurice Zauderer - President; Chief Executive Officer and Director
Albert D. Friedberg - Chairman
Scott E. Royer - Chief Financial Officer
Chrystyna Bedrij Stecyk - Director
Jacob B. Frieberg - Director

Peer Information
Vaccinex, Inc. (CORR.)
Vaccinex, Inc. (RSPI)
Vaccinex, Inc. (CGXP)
Vaccinex, Inc. (BGEN)
Vaccinex, Inc. (GTBP)
Vaccinex, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 918640103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 08/13/21
Share - Related Items
Shares Outstanding: 28.45
Most Recent Split Date: (:1)
Beta: 1.74
Market Capitalization: $81.37 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.14 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.57
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 42.22%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/21 - -616.20
12/31/20 - -
09/30/20 - -
ROA
03/31/21 - -176.15
12/31/20 - -300.48
09/30/20 - -367.05
Current Ratio
03/31/21 - 4.48
12/31/20 - 0.86
09/30/20 - 1.32
Quick Ratio
03/31/21 - 4.48
12/31/20 - 0.86
09/30/20 - 1.32
Operating Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Net Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Pre-Tax Margin
03/31/21 - -3,141.78
12/31/20 - -4,616.16
09/30/20 - -57,460.00
Book Value
03/31/21 - 0.80
12/31/20 - -0.12
09/30/20 - 0.19
Inventory Turnover
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Equity
03/31/21 - 0.05
12/31/20 - -
09/30/20 - 0.30
Debt-to-Capital
03/31/21 - 4.74
12/31/20 - -
09/30/20 - 23.15
 

Powered by Zacks Investment Research ©